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Introduction
Serotonin toxicity is a drug-induced toxidrome that is
a condition of serotonergic hyperstimulation. It is still
commonly referred to as serotonin syndrome. How-
ever, it is not a discrete syndrome, but represents a
spectrum of serotonergic effects.1,2 Serotonin acts cen-
trally as a modulator of exciting neurotransmission.
Serotonergic neurons play an integral part in the reg-
ulation of wakefulness, affective behavior, food intake,
thermoregulation, migraine, emesis, and sexual behavior.
In the periphery, serotonin assists in the regulation of
vascular tone and gastrointestinal motility.3 In humans,
serotonin is derived from dietary tryptophan, which is
converted to 5-hydroxytryptophan and then to sero-
tonin. After transport into cells, serotonin is degraded
mainly by monoamine oxidase (MAO). MAO-A is more
significant than MAO-B in this process.1 Serotonergic
excess can be caused by drug interactions, overdose of
a serotonergic drug, or as a complication of therapy.
Serotonergic drug interactions, particularly when 2
drugs increase serotonergic transmission through dif-
ferent mechanisms, are a common cause of serotonin
toxicity.2 It typically results from the combination 
of MAO inhibitors (MAOI) with other serotonergic
agents. The 3 important mechanisms, in relation to
severe serotonin toxicity, are inhibition of reuptake,
presynaptic release, and MAO inhibition.2 There have
been reports of fatalities from moclobemide alone and
in combination with clomipramine, citalopram and
paroxetine.4 Professor Whyte’s research group at the
Hunter Area Toxicology Service (HATS) in Australia
has maintained a prospective clinical database of all
poisonings since 1987. The HATS data indicate that
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it is only the higher elevations of serotonin resulting
from MAOI plus serotonin reuptake inhibitor (SRI)
combinations that are likely to induce hyperpyrexia and
death.5 We report a case of serotonin toxicity resulting
from the combination of paroxetine, selegiline and
moclobemide in therapeutic doses.
Case Report
A 53-year-old woman presented to the emergency
department with fever and consciousness disturbance
on the day after changing prescriptions. Her past history
was significant for multiple system atrophy, secondary
Parkinsonism and depression for about 5 years, and
neurogenic bladder dysfunction with several episodes
of urinary tract infection. Her medications included
paroxetine 20 mg qd, selegiline 5 mg bid, midodrine
2.5 mg/1.25 mg bid, biperiden 2 mg tid, and ginkgo-
flavone 40 mg bid. Because of incomplete response to
this regimen, the day before admission, moclobemide
(150 mg tid) had been prescribed in place of paroxe-
tine. The patient took paroxetine in the morning and
moclobemide after lunch and dinner. A few hours (at
10 pm) after her second dose of moclobemide, she
developed stiffness, ataxia and diaphoresis. Hyperther-
mia and confusion were also noted 2 hours later. She
was sent to our hospital 8 hours after the second dose
of moclobemide.
In the emergency department, she was confused
and disoriented. Glasgow coma scale was E1V2M5.
Vital signs were: blood pressure, 154/74 mmHg;
pulse, 132 beats/minute; respiratory rate, 20 beats/
minute; body temperature, 39.7°C. Mydriasis, ocular
clonus, diaphoresis, tremor, neck stiffness, limb rigidity,
hyperreflexia and positive Babinski’s sign (left side) were
also noted. Biochemical and hematological studies were
remarkable, with a leukocyte count of 13,200/mm3
(neutrophils 82%, lymphocytes 15%) and glucose level
of 169 mg/dL only. Urinalysis was normal, as were
cultures of blood and urine. Brain computed tomog-
raphy disclosed mild brain atrophy. Cerebrospinal fluid
analyses showed normal cell count, protein and glu-
cose, and were negative for microbiological stains and
cultures. Chest radiography was normal and electro-
cardiography confirmed sinus tachycardia. Serotonin
toxicity was suspected. The patient’s medications were
discontinued, and she was treated with intravenous
fluid and supportive care. The fever persisted for only
24 hours, and she achieved complete recovery 3 days
later. She had recurrent fever and urinary tract infec-
tion on the 4th day of hospitalization but recovered
with antibiotic management.
Discussion
The typical clinical features of serotonin toxicity in
humans, derived from the HATS data, are: (1) neuro-
muscular hyperactivity: tremor, clonus, myoclonus and
hyperreflexia and, in the advanced stage, pyramidal
rigidity; (2) autonomic hyperactivity: diaphoresis, fever,
mydriasis, tachycardia, moderately elevated blood pres-
sure and tachypnea; and (3) altered mental status: ex-
citement and agitation, with confusion in the advanced
stages only.5 The diagnosis of serotonin toxicity is made
on a clinical basis. A strong clinical suspicion, known
exposure to serotonergic agents, demonstration of spe-
cific signs and symptoms, and exclusion of other medical
and psychiatric conditions are required for diagnosis.
This patient’s symptomology included fever, hyper-
tension, mydriasis, and confusion; therefore, differen-
tial diagnoses should include anticholinergic toxicity
and sympathomimetic toxicity. Neither anticholinergic
syndrome nor sympathomimetic syndrome have fea-
tures of neuromuscular excitation.6 Our patient had
been on medications with anticholinergic and sympa-
thomimetic effects for some time without incident.
She presented with tremor, ocular clonus, diaphoresis,
hyperthermia, confusion, hypertension, tachycardia,
tachypnea and mydriasis rapidly after the second dose
of a new serotonergic drug in her regimen. The find-
ings were consistent with the diagnosis of serotonin
toxicity.
Serotonin toxicity is a disorder that can be caused by
the use of drugs or drug combinations that increase
intrasynaptic serotonin. It most often occurs when 2
or more drugs that increase serotonin availability by
different mechanisms are used simultaneously. It may
develop after therapeutic use or overdose. In our case,
there were 3 drugs with the potential to increase sero-
tonin, i.e. paroxetine, moclobemide and selegiline.
Paroxetine is a selective serotonin reuptake inhib-
itor (SSRI). The effective therapeutic dose range is
10–60 mg daily. The half-life is 15–22 hours, and it is
significantly prolonged in older patients. Considerable
intersubject variation is observed, as demonstrated by
the range of half-lives between 3.8 and 65 hours.7
Paroxetine’s potency is the greatest among the SSRIs.
The metabolites of paroxetine, unlike fluoxetine, are
not active. Paroxetine and fluoxetine show the greatest
inhibition of CYP2D6. If a patient does not respond
to paroxetine, 2 weeks should elapse before beginning
MAOI therapy.2,3
Moclobemide, an MAOI, is a reversible competi-
tive selective inhibitor of MAO-A, with a wide spec-
trum of antidepressant activity.8 It is devoid of the
major problems that discredited the first generation of
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irreversible, mixed inhibitors of MAO-A and MAO-B.
However, moclobemide loses selectivity for MAO-A
at higher doses. The elimination half-life of moclobe-
mide is rapid, in the range of 1–3 hours. The drug is
almost completely metabolized in the liver by 2 en-
zymes, CYP2C19 and CYP2D6.8 Moclobemide does
not precipitate serotonin toxicity in overdose by itself,
nor does it produce serotonergic side effects in clinical
use.9 When switching treatment from moclobemide
to SSRI, a washout period of 24 hours is sufficient.
Selegiline, a derivative of methamphetamine, is an
irreversible selective MAO-B inhibitor. Selegiline is
used for the treatment of early-stage Parkinson’s dis-
ease, depression and senile dementia.10 It leaves those
peripheral mechanisms intact that normally prevent 
a hypertensive response following tyramine reaction.
Dietary restrictions are common for MAOI treatments,
but special dietary restrictions for lower doses have been
found to be unnecessary.9 For its selectivity, selegiline
has relatively small potential for serotonin toxicity.
Selegiline is extensively metabolized to methamphet-
amine, amphetamine and N-desmethylselegiline.11 In
selegiline overdose, patients may also exhibit clinical
effects similar to those of methamphetamine. In the
clinical setting, concurrent use of selegiline and par-
oxetine is not contraindicated. However, concurrent
administration of selegiline with antidepressants may
produce profound serotonergic toxicity in vulnerable
patients.12,13
Both moclobemide and paroxetine are substrates
and inhibitors of CYP2D6. Major P450 interaction
both ways may occur with expected substantial eleva-
tions in the blood levels of both drugs, thereby greatly
increasing the likelihood of serotonin toxicity.2 The
risk with combined moclobemide and SRIs is almost
certainly much lower than that with older irreversible
MAOIs combined with SRIs. However, the combina-
tion of moclobemide and SRI still represents a risky
strategy.2 The use of such a potentially risky combina-
tion therapy must be justified. Isbister et al’s case series
of 106 moclobemide overdoses from the HATS data-
base revealed neither serotonin toxicity nor seroto-
nergic signs in cases of moclobemide alone (32 cases)
or moclobemide plus another nonserotonergic drug
(52 cases). Eleven (52%) of 21 patients who coingested
a serotonergic drug developed serotonin toxicity,
which was significantly more than the 1 (3%) of 33
moclobemide-alone overdoses. Serotonin toxicity oc-
curred even though the other serotonergic drug had
often been ingested only in therapeutic quantities, not
as an overdose. In 6 of these 21 cases, severe serotonin
toxicity developed with a temperature >38.5°C and
muscle rigidity requiring intubation and paralysis.4
Our patient took both selegiline and paroxetine
without the development of side effects before the
addition of moclobemide. Because moclobemide is
safer than the old irreversible MAOI, some studies have
claimed that a washout period is not necessary when
switching therapy from an SSRI to moclobemide.9,14
In vulnerable patients, the combination of selegiline,
paroxetine and moclobemide in therapeutic doses
may have the potential to induce moderate serotonin
toxicity, as in our patient.
To diagnose serotonin toxicity, the clinician must
retain a high index of suspicion and exclude other
medical and psychiatric conditions. Serotonin toxicity
is a serious and sometimes fatal event. For this reason,
combination therapy of any MAOI, including moclobe-
mide, and any potent SSRI should be avoided. If a
patient does not respond to an SSRI, it is prudent 
to wait for 2 weeks (5 weeks for fluoxetine) before
beginning MAOI therapy. Serotonin toxicity should
not be viewed as an idiosyncratic reaction, but rather
as a predictable one with variability in occurrence and
severity among patients. Clinicians who are aware of
the potential for serotonin toxicity should be able to
recognize and treat or, ideally, anticipate and avoid
this pharmacodynamically-mediated interaction that
may occur between prescribed drugs.
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